This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline liver function testing (AST or ALT) within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, cyclosporine or cyclophosphamide during the measurement year.
Measure Specs
General Information
Numerator
Patients in the denominator who received liver function testing within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, cyclosporine or cyclophosphamide during the measurement year.
Denominator
Patients >=18 years old with a history of rheumatoid arthritis and a new start of sulfasalazine, methotrexate, leflunomide, azathioprine, cyclosporine or cyclophosphamide anytime from the beginning of the measurement year to 14 days prior to the end of the measurement year. (This list of DMARDs will hereafter be refered to as ´DMARD needing baseline LFT´ )
Exclusions
The measure excludes patients who have had an inpatient hospitalization during the measurement year because UB04 claims do not document individual lab tests ordered during an inpatient stay.
Public Comments